LaunchTrends: Entyvio (US) (Wave 2) | 2015

Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market following launch. The report evaluates physicians’ current awareness and familiarity with Entyvio, its advantages and disadvantages compared with currently available therapies, the current and anticipated usage of the drug, as well as the manufacturer’s promotional activity.

Contact sales account_box

Crohn's Disease US 2015

Report

Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)

First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…

north_east

Report

Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…

north_east

Report

Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…

north_east

Report

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…

north_east

Report

Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)

The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…

north_east

Product logins

LaunchTrends: Entyvio (US) (Wave 2) | 2015

Related Market Assessment Reports

Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)

Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)

Follow us

Contact us